Biotechnology News and Research

RSS

HbA1c glucose monitoring test not effective for diagnosing diabetes patients with kidney failure

The gold standard long-term glucose monitoring test for patients with diabetes proved to be of limited value in dialysis patients, according to a new study at Wake Forest Baptist Medical Center.

1 Jun 2011

Research: Gene mutation causes eye disease glaucoma

It is a mutation in a gene that causes the eye disease glaucoma, according to collaborative research conducted by Swedish, Tunisian, and American researchers. The findings were recently published in the journal Nature Genetics.

31 May 2011

Life Technologies launches new genomic analysis software

Addressing the issue of data overload from next-generation sequencers, Life Technologies Corporation today launched its LifeScope 2.0 Genomic Analysis Software, a significantly enhanced bioinformatics system for analyzing data from genomic sequencing instruments to study human disease such as cancer.

27 May 2011

Transgenomic secures exclusive license from Montefiore for cancer predictive markers

Transgenomic, Inc. announced today that it has acquired an exclusive worldwide license to Montefiore Medical Center's patent application, "Method of Determining the Sensitivity of Cancer Cells to EGFR Inhibitors including cetuximab, panitumumab and erlotinib".

27 May 2011

BioDiscovery, Affymetrix enter co-marketing agreement for OncoScan FFPE Express Service

Affymetrix, Inc. today announced a co-marketing agreement naming BioDiscovery, Inc. its preferred software provider for Affymetrix OncoScan FFPE Express Service data analysis.

27 May 2011

Nuron secures option, license deal to develop NU400 for Relapse Remitting Multiple Sclerosis

Nuron Biotech Inc., a specialty biologics and vaccines company, today announced that it has secured an exclusive option and license agreement utilizing PolyTherics' site-specific TheraPEG PEGylation technology to develop NU400, a long-acting version of Nuron's proprietary recombinant human interferon beta-1b.

27 May 2011

PAREXEL, Pfizer partner to provide clinical development services

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has been selected as one of two strategic partners by Pfizer Inc. to provide clinical development services.

From Parexel 27 May 2011

Neurologix presents NLX-P101 Phase 2 trial in Parkinson's disease at 10th INS World Congress

Neurologix, Inc. announced the presentation today of efficacy results through one year of follow-up in patients treated as part of the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease.

27 May 2011

Bayer, Epitomics enter service agreement for antibody technology

Epitomics, Inc. announced today that it has signed a service agreement with Bayer Schering Pharma AG, Germany.

27 May 2011

Medicago, USAMRIID enter research collaboration for Ebola vaccine candidate

Medicago Inc., a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has entered into a research collaboration agreement with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) for the development of a plant-based VLP vaccine candidate for the prevention of Ebola. Ebola is a very serious hemorrhagic fever virus for which no licensed treatment or vaccine exists.

26 May 2011

iBioLaunch Platform successfully expresses hookworm-derived molecule for potential vaccine

iBio, Inc. today announced that its proprietary iBioLaunch Platform successfully expressed the hookworm-derived molecule known as NaAPR1M-74, which will be evaluated as a potential vaccine candidate for human hookworm disease.

26 May 2011

BioCryst presents positive data from two BCX4208 Phase 2 studies in gout at EULAR 2011

BioCryst Pharmaceuticals, Inc. presented positive data from its two completed, randomized, double-blind, placebo-controlled Phase 2 studies of BCX4208 in patients with gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, U.K.

26 May 2011

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that favorable clinical data on two ImmunoGen-created TAP compounds - IMGN901 and SAR3419 - are being presented at the ASCO 2011 Annual Meeting taking place in Chicago, IL, June 4-8, 2011.

26 May 2011

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology annual meeting in Chicago that indicates combining its investigational therapy afatinib with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer who developed acquired resistance to treatment with a reversible EGFR tyrosine kinase inhibitor.

26 May 2011

NWBT accelerates addition of clinical sites for new enrollment into ongoing GBM brain cancer trial

Northwest Biotherapeutics today announced that it has accelerated the addition of clinical trial sites, exceeding its projections for the doubling of such sites across the U.S. this calendar quarter, for enrollment of new patients into the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax immune therapy for Glioblastoma multiforme, the most lethal form of brain cancer.

26 May 2011

AIBioTech works with U.S. FDA to keep Sports X Factor genetic test available to consumers

American International Biotechnology Services today announced it is working with the U.S. Food and Drug Administration to keep its Sports X Factor genetic test available to consumers.

26 May 2011

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

Ardea Biosciences, Inc. announced that additional positive clinical and preclinical results from its development program of lesinurad, the Company's lead product candidate for the treatment of hyperuricemia and gout, were presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism in London, UK.

26 May 2011

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA plus prednisone compared to patients treated with prednisone plus placebo.

26 May 2011

PolyMedix presents new pre-clinical data on antimicrobial compounds at two scientific meetings

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced today that new pre-clinical data for its novel, defensin-mimetic antimicrobial compounds was recently presented at two prestigious scientific meetings, including the American Society of Microbiology.

25 May 2011

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Today, Biogen Idec will join the global multiple sclerosis (MS) community in celebrating the third annual World MS Day. Biogen Idec continues to be the industry leader in researching and providing groundbreaking therapies for MS. So far in 2011, the company has brought more hope to MS patients through a number of significant milestones.

25 May 2011

Biotechnology News and Research

HbA1c glucose monitoring test not effective for diagnosing diabetes patients with kidney failure

Research: Gene mutation causes eye disease glaucoma

Life Technologies launches new genomic analysis software

Transgenomic secures exclusive license from Montefiore for cancer predictive markers

BioDiscovery, Affymetrix enter co-marketing agreement for OncoScan FFPE Express Service

Nuron secures option, license deal to develop NU400 for Relapse Remitting Multiple Sclerosis

PAREXEL, Pfizer partner to provide clinical development services

Neurologix presents NLX-P101 Phase 2 trial in Parkinson's disease at 10th INS World Congress

Bayer, Epitomics enter service agreement for antibody technology

Medicago, USAMRIID enter research collaboration for Ebola vaccine candidate

iBioLaunch Platform successfully expresses hookworm-derived molecule for potential vaccine

BioCryst presents positive data from two BCX4208 Phase 2 studies in gout at EULAR 2011

ImmunoGen's clinical data on IMGN901 and SAR3419 to be presented at ASCO 2011

Boehringer Ingelheim's new afatinib-cetuximab phase Ib data in NSCLC presented at ASCO 2011

NWBT accelerates addition of clinical sites for new enrollment into ongoing GBM brain cancer trial

AIBioTech works with U.S. FDA to keep Sports X Factor genetic test available to consumers

Ardea reports additional results from lesinurad-allopurinol Phase 2b study in hyperuricemia, gout

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

PolyMedix presents new pre-clinical data on antimicrobial compounds at two scientific meetings

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News